These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2011-004481-15 An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations 2018-10-31 bad-data
Listed as ongoing, but also has a completion date 2012-001896-35 A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve... 2015-12-31 bad-data
Ongoing 2013-002609-78 A randomised open-label phase II trial of consolidation ipilimumab in limited-stage SCLC after chemo-radiotherapy not-yet-due
Other 2013-003156-21 A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC not-yet-due
Ongoing 2014-005097-11 A feasibility trial evaluating anti-PD1 nivolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC not-yet-due
Not reported 2014-005098-35 Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutations 2017-09-15 due-trials
Ongoing 2016-002029-12 A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M not-yet-due
Ongoing 2016-002062-31 A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma not-yet-due
Ongoing 2017-002063-17 A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC not-yet-due